Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donald S Robinson

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Psychopharmacology Bulletin|December 11, 2002
Monoamine oxidase inhibitors: a new generationDonald S Robinson
Journal of Clinical Psychopharmacology|January 8, 2004
Dosing strategies for antidepressant clinical trials: a commentaryDonald S Robinson, Arif Khan
Journal of Clinical Psychopharmacology|July 17, 2007
Why do clinical trials fail?Karl Rickels, Donald S Robinson
Journal of Clinical Psychopharmacology|October 19, 2017
Antidepressant Trials: Are the Diminishing Effect Sizes of Efficacy Trials Avoidable?Karl Rickels, Donald S Robinson
Journal of Clinical Psychopharmacology|June 11, 2009
Comments on "Clinical trials of antidepressants: time to shift to a new model" by Dr KatzKarl Rickels, Donald S Robinson
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|November 10, 2015
Albert SjoerdsmaWalter M Lovenberg, Donald S Robinson
Journal of Affective Disorders|June 15, 2007
The selegiline transdermal system in major depressive disorder: a systematic review of safety and tolerabilityDonald S Robinson, Jay D Amsterdam
Clinical Therapeutics|July 16, 2003
A review of the efficacy and tolerability of immediate-release and extended-release formulations of gepironeDonald S Robinson, J M Ad Sitsen, Michael Gibertini
International Clinical Psychopharmacology|November 20, 2013
Vilazodone in the treatment of major depressive disorder: efficacy across symptoms and severity of depressionArif Khan, Angelo Sambunaris, John Edwards, et al.
The Journal of Clinical Psychiatry|October 5, 2006
Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trialAlan D Feiger, Karl Rickels, Moira A Rynn, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Psychopharmacology Bulletin|December 11, 2002
Monoamine oxidase inhibitors: a new generationDonald S Robinson
Journal of Clinical Psychopharmacology|January 8, 2004
Dosing strategies for antidepressant clinical trials: a commentaryDonald S Robinson, Arif Khan
Journal of Clinical Psychopharmacology|July 17, 2007
Why do clinical trials fail?Karl Rickels, Donald S Robinson
Journal of Clinical Psychopharmacology|October 19, 2017
Antidepressant Trials: Are the Diminishing Effect Sizes of Efficacy Trials Avoidable?Karl Rickels, Donald S Robinson
Journal of Clinical Psychopharmacology|June 11, 2009
Comments on "Clinical trials of antidepressants: time to shift to a new model" by Dr KatzKarl Rickels, Donald S Robinson
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|November 10, 2015
Albert SjoerdsmaWalter M Lovenberg, Donald S Robinson
Journal of Affective Disorders|June 15, 2007
The selegiline transdermal system in major depressive disorder: a systematic review of safety and tolerabilityDonald S Robinson, Jay D Amsterdam
Clinical Therapeutics|July 16, 2003
A review of the efficacy and tolerability of immediate-release and extended-release formulations of gepironeDonald S Robinson, J M Ad Sitsen, Michael Gibertini
International Clinical Psychopharmacology|November 20, 2013
Vilazodone in the treatment of major depressive disorder: efficacy across symptoms and severity of depressionArif Khan, Angelo Sambunaris, John Edwards, et al.
The Journal of Clinical Psychiatry|October 5, 2006
Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trialAlan D Feiger, Karl Rickels, Moira A Rynn, et al.
Pageof 2